Computational modeling of the immune response in multiple sclerosis using epimod framework

Background Multiple Sclerosis (MS) represents nowadays in Europe the leading cause of non-traumatic disabilities in young adults, with more than 700,000 EU cases. Although huge strides have been made over the years, MS etiology remains partially unknown. Furthermore, the presence of various endogenous and exogenous factors can greatly influence the immune response of different individuals, making it difficult to study and understand the disease. This becomes more evident in a personalized-fashion when medical doctors have to choose the best therapy for patient well-being. In this optics, the use of stochastic models, capable of taking into consideration all the fluctuations due to unknown factors and individual variability, is highly advisable. Results We propose a new model to study the immune response in relapsing remitting MS (RRMS), the most common form of MS that is characterized by alternate episodes of symptom exacerbation (relapses) with periods of disease stability (remission). In this new model, both the peripheral lymph node/blood vessel and the central nervous system are explicitly represented. The model was created and analysed using Epimod, our recently developed general framework for modeling complex biological systems. Then the effectiveness of our model was shown by modeling the complex immunological mechanisms characterizing RRMS during its course and under the DAC administration. Conclusions Simulation results have proven the ability of the model to reproduce in silico the immune T cell balance characterizing RRMS course and the DAC effects. Furthermore, they confirmed the importance of a timely intervention on the disease course.

[1]  B. Trapp,et al.  Mechanisms of neuronal dysfunction and degeneration in multiple sclerosis , 2011, Progress in Neurobiology.

[2]  Syed Ijlal Ahmed,et al.  Risk of Multiple Sclerosis in Epstein–Barr Virus Infection , 2019, Cureus.

[3]  Matt Shirley,et al.  Daclizumab: A Review in Relapsing Multiple Sclerosis , 2017, Drugs.

[4]  Marco Beccuti,et al.  30 Years of GreatSPN , 2016 .

[5]  J. Libbey,et al.  Molecular Mimicry in Multiple Sclerosis , 2007, International Review of Neurobiology.

[6]  Alessandro Maglione,et al.  The Meaning of Immune Reconstitution after Alemtuzumab Therapy in Multiple Sclerosis , 2020, Cells.

[7]  W. L. Benedict,et al.  Multiple Sclerosis , 2007, Journal - Michigan State Medical Society.

[8]  D. Sojka,et al.  Mechanisms of regulatory T‐cell suppression – a diverse arsenal for a moving target , 2008, Immunology.

[9]  Milanesi Luciano,et al.  Integrating Petri Nets and Flux Balance Methods in Computational Biology Models : a Methodological and Computational Practice , 2019 .

[10]  Francesco Novelli,et al.  Th22 cells are expanded in multiple sclerosis and are resistant to IFN‐β , 2014, Journal of leukocyte biology.

[11]  Ferdinando Chiacchio,et al.  Relapsing-remitting multiple scleroris and the role of vitamin D: an agent based model , 2014, BCB.

[12]  Abdul Mateen Rajput,et al.  Agent based modeling of Treg-Teff cross regulation in relapsing-remitting multiple sclerosis , 2013, BMC Bioinformatics.

[13]  Daniela Paolotti,et al.  A computational framework for modeling and studying pertussis epidemiology and vaccination , 2020, BMC Bioinformatics.

[14]  Jefferson Becker,et al.  Th17 Cells Pathways in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorders: Pathophysiological and Therapeutic Implications , 2016, Mediators of inflammation.

[15]  Heinz Wiendl,et al.  The role of regulatory T cells in multiple sclerosis , 2008, Nature Clinical Practice Neurology.

[16]  Till Sprenger,et al.  Long-term safety and efficacy of daclizumab beta in relapsing–remitting multiple sclerosis: 6-year results from the SELECTED open-label extension study , 2020, Journal of Neurology.

[17]  F. Quintana,et al.  [Immunopathology of multiple sclerosis]. , 2014, Medicina.

[18]  A. Steelman,et al.  Infection as an Environmental Trigger of Multiple Sclerosis Disease Exacerbation , 2015, Front. Immunol..

[19]  Hong Li,et al.  Efficient formulation of the stochastic simulation algorithm for chemically reacting systems. , 2004, The Journal of chemical physics.

[20]  Francesco Pappalardo,et al.  Agent based modeling of the effects of potential treatments over the blood-brain barrier in multiple sclerosis. , 2015, Journal of immunological methods.

[21]  Michael A. Gibson,et al.  Efficient Exact Stochastic Simulation of Chemical Systems with Many Species and Many Channels , 2000 .

[22]  D. Gillespie Exact Stochastic Simulation of Coupled Chemical Reactions , 1977 .

[23]  T. Mcclanahan,et al.  IL-23 drives a pathogenic T cell population that induces autoimmune inflammation , 2005, The Journal of experimental medicine.

[24]  Marco Beccuti,et al.  A computational approach based on the colored Petri net formalism for studying multiple sclerosis , 2019, BMC Bioinformatics.

[25]  Jos H. Beijnen,et al.  Clinical Pharmacokinetics of Therapeutic Monoclonal Antibodies , 2010, Clinical pharmacokinetics.

[26]  E. Andrès,et al.  CD56bright natural killer (NK) cells: an important NK cell subset , 2009, Immunology.

[27]  Beccuti Marco,et al.  Estimating Daclizumab effects in Multiple Sclerosis using Stochastic Symmetric Nets , 2018, 2018 IEEE International Conference on Bioinformatics and Biomedicine (BIBM).

[28]  D. Gillespie Approximate accelerated stochastic simulation of chemically reacting systems , 2001 .

[29]  Marco Ajmone Marsan,et al.  Modelling with Generalized Stochastic Petri Nets , 1995, PERV.

[30]  Nathalie Arbour,et al.  Human TH17 lymphocytes promote blood-brain barrier disruption and central nervous system inflammation , 2007, Nature Medicine.

[31]  Behzad Baradaran,et al.  The role of B cells in the immunopathogenesis of multiple sclerosis , 2020, Immunology.

[32]  Marco Beccuti,et al.  Integrating Petri Nets and Flux Balance Methods in Computational Biology Models: a Methodological and Computational Practice , 2020, Fundam. Informaticae.

[33]  Laura Conti,et al.  T‐helper 17 cells expand in multiple sclerosis and are inhibited by interferon‐β , 2009, Annals of neurology.

[34]  F Zipp,et al.  ECTRIMS/EAN guideline on the pharmacological treatment of people with multiple sclerosis , 2018, European journal of neurology.

[35]  Joaquín Goñi,et al.  Modeling the effector - regulatory T cell cross-regulation reveals the intrinsic character of relapses in Multiple Sclerosis , 2011, BMC Systems Biology.

[36]  Gavin Giovannoni,et al.  Epstein–Barr Virus in Multiple Sclerosis: Theory and Emerging Immunotherapies , 2019, Trends in Molecular Medicine.

[37]  Ryozo Ohno,et al.  [Cerebrospinal fluid in multiple sclerosis]. , 2003, Nihon rinsho. Japanese journal of clinical medicine.

[38]  Antonio Uccelli,et al.  CD56bright Natural Killer Cells: A Possible Biomarker of Different Treatments in Multiple Sclerosis , 2020, Journal of clinical medicine.

[39]  Jia Newcombe,et al.  Interleukin-17 production in central nervous system-infiltrating T cells and glial cells is associated with active disease in multiple sclerosis. , 2008, The American journal of pathology.